Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression [Phase 1, Phase 2]

View source ↗

Summary

A2 Biotherapeutics is evaluating A2B530, a logic-gated CAR T therapy, in Phase 1/2 trials for CEA-expressing solid tumors that have lost HLA-A*02 expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• A2B530

Snippet

Sponsor: A2 Biotherapeutics Inc. | Conditions: Solid Tumor, Adult, Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING